104 related articles for article (PubMed ID: 38714355)
21. Therapeutic Vulnerability to ATR Inhibition in Concurrent
Yuan M; Eberhart CG; Pratilas CA; Blakeley JO; Davis C; Stojanova M; Reilly K; Meeker AK; Heaphy CM; Rodriguez FJ
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740680
[TBL] [Abstract][Full Text] [Related]
22. The molecular landscape of glioma in patients with Neurofibromatosis 1.
D'Angelo F; Ceccarelli M; Tala ; Garofano L; Zhang J; Frattini V; Caruso FP; Lewis G; Alfaro KD; Bauchet L; Berzero G; Cachia D; Cangiano M; Capelle L; de Groot J; DiMeco F; Ducray F; Farah W; Finocchiaro G; Goutagny S; Kamiya-Matsuoka C; Lavarino C; Loiseau H; Lorgis V; Marras CE; McCutcheon I; Nam DH; Ronchi S; Saletti V; Seizeur R; Slopis J; Suñol M; Vandenbos F; Varlet P; Vidaud D; Watts C; Tabar V; Reuss DE; Kim SK; Meyronet D; Mokhtari K; Salvador H; Bhat KP; Eoli M; Sanson M; Lasorella A; Iavarone A
Nat Med; 2019 Jan; 25(1):176-187. PubMed ID: 30531922
[TBL] [Abstract][Full Text] [Related]
23. Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas.
Papalia H; Audic F; Rivière GR; Verschuur A; André N
Ecancermedicalscience; 2018; 12():862. PubMed ID: 30174724
[TBL] [Abstract][Full Text] [Related]
24. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.
House RRJ; Tovar EA; Redlon LN; Essenburg CJ; Dischinger PS; Ellis AE; Beddows I; Sheldon RD; Lien EC; Graveel CR; Steensma MR
Mol Metab; 2024 Feb; 80():101876. PubMed ID: 38216123
[TBL] [Abstract][Full Text] [Related]
25. [Neurofibromatosis von Recklinghausen type 1 (NF1) - clinical picture and molecular-genetics diagnostic].
Petrák B; Bendová Š; Lisý J; Kraus J; Zatrapa T; Glombová M; Zámečník J
Cesk Patol; 2015; 51(1):34-40. PubMed ID: 25671360
[TBL] [Abstract][Full Text] [Related]
26. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
27. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
28. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
29. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
30. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K
Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491
[TBL] [Abstract][Full Text] [Related]
31. Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells.
Allaway RJ; Wood MD; Downey SL; Bouley SJ; Traphagen NA; Wells JD; Batra J; Melancon SN; Ringelberg C; Seibel W; Ratner N; Sanchez Y
Oncotarget; 2018 Mar; 9(22):15860-15875. PubMed ID: 29662612
[TBL] [Abstract][Full Text] [Related]
32. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
34. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
Banerjee S; Byrd JN; Gianino SM; Harpstrite SE; Rodriguez FJ; Tuskan RG; Reilly KM; Piwnica-Worms DR; Gutmann DH
Cancer Res; 2010 Feb; 70(4):1356-66. PubMed ID: 20124472
[TBL] [Abstract][Full Text] [Related]
35. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
[TBL] [Abstract][Full Text] [Related]
36. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
[TBL] [Abstract][Full Text] [Related]
37. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
39. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro.
Ingram DA; Hiatt K; King AJ; Fisher L; Shivakumar R; Derstine C; Wenning MJ; Diaz B; Travers JB; Hood A; Marshall M; Williams DA; Clapp DW
J Exp Med; 2001 Jul; 194(1):57-69. PubMed ID: 11435472
[TBL] [Abstract][Full Text] [Related]
40. The NF1 somatic mutational landscape in sporadic human cancers.
Philpott C; Tovell H; Frayling IM; Cooper DN; Upadhyaya M
Hum Genomics; 2017 Jun; 11(1):13. PubMed ID: 28637487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
